NCT04998747View on ClinicalTrials.gov

A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

August 29, 2023

Primary Completion Date

August 2, 2025

Study Completion Date

August 28, 2025

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG

AMG 701

AMG 701 will be administered as SC or intravenous injection.

DRUG

AMG 701

AMG 701 will be administered as SC injection.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY

NCT04998747 - A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Biotech Hunter | Biotech Hunter